Furthermore, the study found that AS-IV may further exert its anti-HSC activation and anti-liver fibrosis effects through by regulating the C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C chemokine receptor type 4 (CXCR4) signaling axis (Su et al., 2023). This evidence concerns the gene CXCL12 and Hepatic fibrosis.